Get 40% Off
💰 Warren Buffett reveals a $6.72 billion stake in ChubbCopy Portfolios

KemPharm in-licenses Tourette/ADHD candidate from Genco; shares up 7%

Published 10/04/2017, 10:35 AM
© Reuters.  KemPharm in-licenses Tourette/ADHD candidate from Genco; shares up 7%
ZVRA
-
  • Thinly traded nano cap KemPharm (KMPH +6.6%) is up on light volume on the heels of its announcement that it inked an agreement with Genco Sciences, LLC for exclusive rights to develop and commercialize its product candidate for the treatment of children with Tourette's syndrome who also suffer from attention deficit hyperactivity disorder (ADHD).
  • KemPharm plans to leverage Genco's proprietary nanoparticulate amphetamine technology to develop a prodrug for the indication.
  • Under the terms of the contract, KemPharm will be responsible for financing and product development. Genco will be eligible to receive milestone payments and royalties. Specific financial terms are not disclosed.
  • Now read: KemPharm (KMPH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.